Document:

EX-10.2

 Exhibit 10.2 

COLLABORATION AGREEMENT 
 by and
between 
 UROVANT SCIENCES GMBH 

and 
 KYORIN PHARMACEUTICAL CO.,
LTD. 
  
  

Dated as of August 24, 2017 
  

 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 COLLABORATION AGREEMENT 

This Collaboration Agreement (this “Agreement”) dated August 24, 2017 (“Effective Date”), is by and
between Urovant Sciences GmbH, having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Urovant”), and Kyorin Pharmaceutical Co., Ltd., having a place of business at 6, Kanda Surugadai
4-chome, Chiyoda-ku, Tokyo 101-8311, Japan (“Kyorin”). 

RECITALS 
 WHEREAS,
Urovant is a pharmaceutical company engaged in the research, development, and commercialization of products useful in the amelioration, treatment, or prevention of human diseases and conditions in the field of Urology; 

WHEREAS, Kyorin is a pharmaceutical company engaged in the research, development, and commercialization of products useful in the
amelioration, treatment, or prevention of human diseases and conditions in a variety of fields, including Urology; 
 WHEREAS,
Urovant and Kyorin have obtained from Merck Sharp & Dohme Corp. certain licenses to products containing an active pharmaceutical ingredient called Vibegron (also known as MK-4618) in their respective
territories; 
 WHEREAS, Urovant and Kyorin made the Letter Agreement, in which the Parties confirmed their understanding of the
exchange of certain confidential technical and business information and other collaboration relationship items relating to Vibegron; 

WHEREAS, Urovant and Kyorin desire to enter into an agreement to specify the provisions of an additional information exchange,
specifically SAS datasets and portions of trial master files (“TMFs”), and other collaboration relationship items, and to set forth certain additional provisions related hereto. 

NOW, THEREFORE, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

  

	1.1	 “Affiliate” of a Party to this Agreement means and includes any Person: (a) fifty
percent (50%) or more of the voting stock or other equity interest of which is owned, directly or indirectly, by that Party; (b) which owns, directly or indirectly, fifty percent (50%) or more of the voting stock or other equity interest of
that Party; (c) fifty percent (50%) or more of the voting stock or other equity interest of which is owned, directly or indirectly, by a Person that owns, directly or indirectly, fifty percent (50%) or more of the voting stock or other equity
interest of that Party; (d) for which that Party has the right to elect a majority of the members of the board of directors, or to appoint the chief executive officer, general manager or other senior management officials; or (e) that
possesses, directly or indirectly, the power to direct, or cause the direction of, the management and policies of that Party. 

  

	1.2	 “Agreement” has the meaning set forth in the Preamble. 

  
 -2- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	1.3	 “Applicable Laws” means all applicable laws, regulations, rules, decrees, judicial and
administrative orders, and governmental actions, policies and requirements having the force of law in the applicable country or jurisdiction. 

  

	1.4	 “Business Day” means a day other than a Saturday, Sunday, a bank or other public
holiday in the United States or Japan, or a day designated by a Party as its non-business day. 

  

	1.5	 “CCDS” means company core data sheet. 

 

	1.6	 “Change of Control” means the sale of all or substantially all the assets or the equity
of a Party to a Third Party; or any merger, consolidation or acquisition of a Party with, by or into any Third Party. 

  

	1.7	 “Clinical Trial” means any human clinical trial of Vibegron, including any “Phase
IV” post-approval clinical trial. 

  

	1.8	 “CMC” means chemistry, manufacturing, and controls. 

 

	1.9	 “Commercialize” or “Commercialization” means all activities carried
out in the commercialization of Vibegron, including distributing (including, without limitation, importing, exporting, transporting, customs clearance, warehousing, invoicing, handling and delivering Vibegron to customers), advertising, promoting,
marketing, using and selling Vibegron, and booking sales, as applicable. 

  

	1.10	 “Confidential Information” means (a) information not in the public domain that is
disclosed by one Party or its Affiliates to the other Party or its Affiliates in connection with this Agreement and/or the Letter Agreement, including all Kyorin Information, Urovant Information, and all other data and information relating to
Vibegron or the business, marketing, promotion, affairs, research and development activities, results of clinical and non-clinical studies, national and multinational regulatory proceedings and affairs,
finances, manufacturing, plans, contractual relationships and operations of either Party or their Affiliates which is disclosed or provided by or on behalf of one Party to the other Party in connection with this Agreement and (b) the terms and
conditions contained in this Agreement that are not in the public domain. 

  

	1.11	 “Control” or “Controlled” means, with respect to any information,
documentation or Regulatory Materials, the legal authority or right (whether by ownership, license (other than a license granted pursuant to this Agreement) or otherwise) of a Party or its relevant Affiliate, to grant access or rights to such
information, documentation or Regulatory Materials to the other Party as set forth herein without (a) breaching the terms of any agreement with a Third Party, (b) misappropriating the proprietary or trade secret information of a Third
Party, (c) necessitating the consent of a Third Party or (d) requiring any royalty or other payment to any Third Party. 

  

	1.12	 “Develop” or “Development” means the conduct of any and all non-clinical and clinical research and development, including, among other things: drug discovery, toxicology studies, DMPK studies and other non-clinical efforts, statistical
analysis, the design and 

  
 -3- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
conduct of any Clinical Trials, formulation, or regulatory activities relating to Vibegron, that are reasonably required or useful to obtain or maintain any regulatory approvals of Vibegron.

  

	1.13	 “Disclosing Party” has the meaning set forth in Section 4.1 (Nondisclosure and Non-Use). 

  

	1.14	 “Dispute” has the meaning set forth in Section 5.1 (Dispute Resolution).

  

	1.15	 “DMPK” means drug metabolism and pharmacokinetics. 

 

	1.16	 “Effective Date” has the meaning set forth in the Preamble. 

 

	1.17	 “FDA” means the U.S. Food and Drug Administration. 

 

	1.18	 “Government Authority” means any national, regional, municipal, country, or other
governmental, quasi-governmental, administrative or regulatory agency, body or other similar entity in a given jurisdiction, including the FDA, EMA, and PMDA. 

 

	1.19	 “ICH” means International Conference on Harmonization. 

 

	1.20	 “IND” means a clinical trial authorization application filed for Vibegron with the
applicable Government Authority in any country prior to beginning a Clinical Trial in that country (including an investigational new drug application filed with the FDA) or other documentation issued by a Government Authority that permits the
conduct of clinical testing of Vibegron in humans in a regulatory jurisdiction. 

  

	1.21	 “Indication” means the use of Vibegron for the treatment, prevention, cure or control
of a specific human disease, disorder, illness or condition. 

  

	1.22	 “Kyorin” has the meaning set forth in the Preamble. 

 

	1.23	 “Kyorin Indemnitee” has the meaning set forth in Section 6.1
(Indemnification by Urovant). 

  

	1.24	 “Kyorin Information” has the meaning set forth in Section 2.1 (Share of Information).

  

	1.25	 “Kyorin Territory” means Japan, Korea, Taiwan, Hong Kong, Indonesia, Cambodia,
Singapore, Thailand, the Philippines, Brunei, Vietnam, Malaysia, Myanmar, and Laos. 

  

	1.26	 “Letter Agreement” means that letter agreement executed by the duly authorized
representatives of the Parties on April 11, 2017. 

  

	1.27	 “Losses” has the meaning set forth in Section 6.1 (Indemnification by Urovant).

  

	1.28	 “MAA” means an application to the appropriate Government Authority for approval to
commercially sell Vibegron (but excluding pricing approval) in a particular jurisdiction (including, without limitation, a new drug application in the United States) and all amendments and supplements thereto. 

  
 -4- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	1.29	 “Manufacture” or “Manufacturing” means all activities by or on behalf
of a Party related to the manufacturing of Vibegron, or any ingredient thereof, including but not limited to test method development and stability testing, formulation, process development, manufacturing for use in
non-clinical or clinical studies, manufacturing scale-up, manufacturing Vibegron for Development or Commercialization, labeling, filling, processing, quality
assurance/quality control development, quality control testing (including in-process release and stability testing), packaging, release of product or any component or ingredient thereof, quality assurance
activities related to manufacturing and release of product, and regulatory activities related to all of the foregoing. 

  

	1.30	 “Party” means each of Urovant or Kyorin, as applicable and “Parties”
means both of Urovant and Kyorin; [***]. 

  

	1.31	 “Person” means any individual, corporation, partnership, limited liability company,
trust, governmental entity, or other legal entity of any nature whatsoever. 

  

	1.32	 “Pharmacovigilance Agreement” has the meaning set forth in Section 2.6
(Pharmacovigilance Agreement). 

  

	1.33	 “Pivotal Study” means a study listed in the “clinical studies” section
(which, as of the Effective Date, is section 14) of an FDA approved package insert. 

  

	1.34	 “PMDA” means the Pharmaceuticals and Medical Devices Agency in Japan.

  

	1.35	 “Receiving Party” has the meaning set forth in Section 4.1 (Nondisclosure and Non-Use). 

  

	1.36	 “Regulatory Materials” means all regulatory applications, registrations, licenses,
authorizations and approvals, all correspondence submitted to or received from a Government Authority (including minutes and official contact reports relating to any communications with any Government Authority), and all reports and documentation in
connection with all clinical and non-clinical studies and tests (including study reports and study protocols, and copies of all interim study analysis, but excluding Module 3 of the Common Technical
Document, Manufacturing data, and drug master files, unless otherwise agreed by the Parties) submitted to any Government Authority, and all data contained in any of the foregoing, including all INDs, clinical and
non-clinical data, adverse event files and complaint files, in each case related to Vibegron. 

  

	1.37	 [***]. 

  

	1.38	 “Term” has the meaning set forth in Section 7.1 (Term). 

 

	1.39	 “Terminated Party” has the meaning set forth in Section 7.5 (Effect of Expiration
or Termination). 

  

	1.40	 “Terminating Party” has the meaning set forth in Section 7.5 (Effect of Expiration
or Termination). 

  
 -5- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	1.41	 “Third Party” means a Person other than Kyorin or Urovant, or any of their Affiliates.

  

	1.42	 “Urology” means the treatment of diseases primarily affecting the male and female
urinary tract and/or urinary bladder, excluding oncology, osteoporosis, and kidney indications. 

  

	1.43	 “Urology Asset License” has the meaning set forth in Section 2.8 (Kyorin Right of
First Review and Negotiation). 

  

	1.44	 “Urology Rights” has the meaning set forth in Section 2.8 (Kyorin Right of First
Review and Negotiation). 

  

	1.45	 “Urovant” has the meaning set forth in the Preamble. 

 

	1.46	 “Urovant Indemnitee” has the meaning set forth in Section 6.2
(Indemnification by Kyorin). 

  

	1.47	 “Urovant Information” has the meaning set forth in Section 2.1 (Share of
Information). 

  

	1.48	 “Urovant Territory” means the entire world excluding the Kyorin Territory.

  

	1.49	 “Vibegron” means any and all pharmaceutical products with any kinds of strength, dosage
form, and formulations containing [***] as an active pharmaceutical ingredient, either alone or in combination with one or more other active pharmaceutical ingredient(s). 

ARTICLE 2 
 COLLABORATION
ON INFORMATION SHARE 
  

	2.1	 Share of Information. In accordance with the provisions of this
Section 2.1 (Share of Information), each Party shall provide to the other Party all information useful or reasonably necessary for the other Party to Develop and Commercialize Vibegron in the other Party’s Territory to the extent available
to such providing Party. For clarity, each Party shall not be required to provide to the other Party any information relating to CMC or Manufacturing except as otherwise agreed by the Parties. For further clarity, each Party shall not be required to
translate any information or provide any original hardcopy or any original file of any information for the purposes of this Section 2.1 (Share of Information). Notwithstanding the foregoing, the Party providing its information hereunder may
request the other Party to arrange, at its cost, for a Third Party agent or contractor to be sent out to an office of such providing Party or any other place designated by the providing Party to take copies of, or computerize such information, or
compensate the providing Party for the costs incurred by the providing Party to take copies of, or computerize such information, which include the cost of a full-time employee of the providing Party. 

 

	 	(a)	 Urovant Information. Urovant shall, within ten (10) Business Days after the date of the request
from Kyorin unless otherwise agreed by the Parties, provide to Kyorin the information listed in Appendix 1 attached hereto. Urovant shall, within ten (10) Business Days after the date of receipt of the finalized minutes of the End of Phase 2
meeting for Vibegron with the FDA, provide a copy of such minutes to Kyorin. 

  
 -6- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
Such information and minutes provided by or on behalf of Urovant to Kyorin in connection with this Agreement (the “Urovant Information”) shall, as between the Parties, remain the
sole property of Urovant. Unless otherwise provided for in this Agreement, Kyorin (i) may use such Urovant Information only for the purpose of the fulfillment of obligations or the exercise of rights under this Agreement, (ii) shall not
use any Urovant Information for any purpose other than as set forth in subsection (i) above, or for the benefit of any Third Party (other than a Kyorin sublicensee and consistent with subsection (i) above), without obtaining Urovant’s
prior written consent, and (iii) shall not provide or otherwise make accessible to any Third Party any Urovant Information for any purpose other than as set forth in subsection (i) above (other than a Kyorin sublicensee(s) and consistent
with subsection (i) above), without obtaining Urovant’s prior written consent; in each case, in accordance with Article 4 (Confidentiality). 

  

	 	(b)	 Kyorin Information. Both Parties acknowledge that under the Letter Agreement Kyorin agreed to provide
and has provided to Urovant, and Urovant agreed to receive and has received from Kyorin, the information listed in Appendix 2 attached hereto. Kyorin shall, promptly after the Effective Date and no later than ten (10) Business Days after
the Effective Date, provide to Urovant the information listed in Appendix 3 attached hereto, including patient-level data as agreed under the Letter Agreement, in the form of the CSR. Kyorin shall, no later than ten (10) Business Days
after the date of PMDA’s acceptance of the MAA submitted by Kyorin to PMDA unless otherwise agreed by the Parties, provide to Urovant the information listed in Appendix 4 attached hereto. Such information provided by or on behalf of Kyorin to
Urovant in connection with this Agreement (the “Kyorin Information”) shall, as between the Parties, remain the sole property of Kyorin. Unless otherwise provided for in this Agreement, Urovant (i) may use such Kyorin
Information only for the purpose of the fulfillment of obligations or the exercise of rights under this Agreement, (ii) shall not use any Kyorin Information for any purpose other than as set forth in subsection (i) above, or for the
benefit of any Third Party (other than a Urovant sublicensee and consistent with subsection (i) above), without obtaining Kyorin’s prior written consent, and (iii) shall not provide or otherwise make accessible to any Third Party any
Kyorin Information for any purpose other than as set forth in subsection (i) above (other than a Urovant sublicensee(s) and consistent with subsection (i) above), without obtaining Kyorin’s prior written consent; in each case, in
accordance with Article 4 (Confidentiality). 

  

	2.2	 Urovant Right of Reference. Kyorin hereby grants to Urovant (and its Affiliates or its
sublicensees) access to, and a right of reference with respect to, all Regulatory Materials Controlled by Kyorin and corresponding documentation, solely for the purposes of (a) Commercializing Vibegron in the Urovant Territory, and
(b) Developing Vibegron in the Urovant Territory (including the use for any meeting with or any submission to the relevant Government Authority, itself or through its sublicensees, for the purpose of obtaining any regulatory approvals of
Vibegron for any Indication), in each case, in accordance with all Applicable Laws. If Urovant requests Kyorin’s assistance to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be

  
 -7- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
necessary or appropriate in order to effect such right of reference, Urovant shall inform Kyorin of such request, and the Parties shall discuss and agree in writing on the terms and conditions
for such assistance; provided, that Kyorin shall, without making any written agreement thereunder, use commercially reasonable efforts to timely answer any questions from Urovant in order to effect the right of reference. 

 

	2.3	 Kyorin Right of Reference. Urovant hereby grants to Kyorin (and its Affiliates or its
sublicensees) access to, and a right of reference with respect to, Regulatory Materials Controlled by Urovant and corresponding documentation, solely for the purposes of (a) Commercializing Vibegron in the Kyorin Territory, and
(b) Developing Vibegron in the Kyorin Territory (including the use for any meeting with or any submission to the relevant Government Authority, itself or through its sublicensees, for the purpose of obtaining any regulatory approvals of
Vibegron for any Indication), in each case, in accordance with all Applicable Laws. If Kyorin requests Urovant’s assistance to execute, acknowledge, and deliver any further documents or instruments and to perform all such other acts as may be
necessary or appropriate in order to effect such right of reference, Kyorin shall inform Urovant of such request, and the Parties shall discuss and agree on in writing the terms and conditions for such assistance; provided, that Urovant
shall, without making any written agreement thereunder, use commercially reasonable efforts to timely answer any questions from Kyorin in order to effect the right of reference. 

 

	2.4	 Regulatory Cooperation. The Parties understand that the assistance under Section 2.2
(Urovant Right of Reference) and Section 2.3 (Kyorin Right of Reference) include the provisions of relevant internal regulatory documents, such as notes and preparation materials, and any materials documenting any clarifications (whether orally
or otherwise) regarding any Regulatory Materials or with respect to which the requesting Party has a right of reference. For the avoidance of doubt, such Party shall not be required to translate any such Regulatory Materials or provide any original
hardcopy or any original file of any Regulatory Material for the purposes of this Section 2.4 (Regulatory Cooperation). 

  

	2.5	 Milestone Payments. Urovant shall pay the following milestone payments to Kyorin:

  

	 	(a)	 [***] within ten (10) Business Days of [***;] 

 

	 	(b)	 [***] within ten (10) Business Days of [***]; 

 

	 	(c)	 (1) If Kyorin receives [***] or (2) if Kyorin receives [***], within ten (10) Business Days of [***];
and 

  

	 	(d)	 [***]. Such milestone payment shall be made within ten (10) Business Days of [***]. 

For clarity, the payments set forth in this Section 2.5 (Milestone Payments) shall be
non-refundable. 
  

	2.6	 Pharmacovigilance Agreement. The Parties shall execute a pharmacovigilance agreement on
reasonable and customary terms that shall provide, among other things, guidelines and responsibilities for (a) the receipt, investigation, recording, review, 

  
 -8- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
communication, reporting, and exchange between the Parties of adverse event reports and other safety information relating to Vibegron such as CCDSs, Safety Signaling, core- RMP, Periodic /
Aggregate reports (DSUR, PBRER) without any consideration, (b) appropriate reconciliation procedures to ensure adequate and compliant exchange of safety data, (c) contact with Government Authorities with respect to the foregoing, and
(d) Urovant’s maintenance of a global safety database with respect to Vibegron at its cost, in each case ((a)–(d)), in accordance with Applicable Law (the “Pharmacovigilance Agreement”). The Pharmacovigilance
Agreement shall contain terms no less stringent than those required by ICH or other applicable guidelines to allow the Parties to meet the applicable regulatory and legal requirements regarding the management of safety data in their respective
Territories. 

  

	2.7	 Disclosure of Collaboration. Without obtaining the prior written consent of the other
Party, neither Party nor its Affiliates may disclose on its website or in its promotional materials that the other Party is a partner of such Party, or utilize the other Party’s name and logo in conjunction with such disclosure. Further, any
publication, news release or other public announcement made by a Party relating to this Agreement or to the performance hereunder, shall first be reviewed and consented by the other Party; provided, that any disclosure required by Applicable
Laws may be made without obtaining the prior written consent of the other Party. Each Party shall provide to the other Party a draft of any public announcement regarding this Agreement or the subject matter thereof, regardless of whether consent is
required, as soon as reasonably practicable under the circumstances prior to its scheduled release. Except under extraordinary circumstances, each Party shall provide the other Party with an advance copy of any such announcement ten
(10) Business Days prior to its scheduled release. Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by Applicable Laws, the Party whose announcement has
been reviewed shall give good faith consideration to removing any information that the reviewing Party reasonably deems to be inappropriate for disclosure. 

  

	2.8	 Kyorin Right of First Review and Negotiation. If, beginning on the Effective
Date and continuing for ten (10) years thereafter, Urovant obtains Japanese rights to any asset(s) for which the primary intended indication at the time of acquisition is Urology, other than Vibegron-related assets (“Urology
Rights”), Urovant shall promptly (but in no event later than thirty (30) days after the date of obtaining such Urology Rights), inform Kyorin that it has obtained such Urology Rights. If Kyorin is interested in evaluating such Urology
Rights, Kyorin shall promptly (but in no event later than ten (10) days after receiving notice from Urovant) inform Urovant of such interest. Urovant shall then promptly (but in no event later than thirty (30) days after receiving an
expression of interest from Kyorin), provide to Kyorin all data and information available to Urovant that is useful or reasonably necessary for evaluating its interest in such Urology Rights. If Kyorin desires to obtain a license to exercise the
Urology Rights (“Urology Asset License”), Kyorin shall, within sixty (60) days after the date of the last receipt of such data and information (which date shall not be extended by subsequent questions or requests from Kyorin),
submit to Urovant a non-binding term sheet proposing the basic terms for such Urology Asset License. Urovant shall consider such Kyorin term sheet and negotiate in good faith with Kyorin the

  
 -9- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
terms for the Urology Asset License for ninety (90) days after the date of the Kyorin term sheet. If the Parties fail to enter into a definitive agreement for the Urology Asset License by
the end of the ninety (90) day good faith negotiation period, Urovant shall have the right to negotiate and enter into such a definitive agreement with any Third Party without bearing further obligations to Kyorin. If Kyorin fails to submit to
Urovant the non-binding term sheet within such sixty (60) day period, then Urovant shall have no further obligation to Kyorin with respect to the Urology Rights. This Section 2.8 (Kyorin Right of
First Review and Negotiation) shall expire upon any Change of Control and shall not extend to any of Urovant’s licensees and sublicensees or its Affiliates’ licensees and sublicensees. 

 

	2.9	 [***] 

ARTICLE 3 
 OTHER
COLLABORATIONS 
  

	3.1	 Other Collaborations. Urovant and Kyorin shall, from time to time during the Term,
evaluate the possibility of further collaborations between the Parties on the Development and Commercialization of Vibegron. 

ARTICLE 4 

CONFIDENTIALITY 
  

	4.1	 Nondisclosure and Non-Use. Each
Party agrees that, during the Term and for a period of ten (10) years thereafter, a Party (the “Receiving Party”) receiving Confidential Information of the other Party (the “Disclosing Party”) shall
(a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own confidential or proprietary information of similar kind and value, (b) not disclose such
Confidential Information to any Third Party (other than its sublicensee and consistent with Section 2.1(a)(i) or Section 2.1(b)(i)) without obtaining the prior written consent of the Disclosing Party, except for disclosures expressly
permitted in this Article 4 (Confidentiality), and (c) not use such Confidential Information for any purpose, except to exercise its right and perform its obligations under this Agreement (it being understood that this Section 4.1
(Nondisclosure and Non-Use) shall not create or imply any rights or licenses not expressly granted under this Agreement). Notwithstanding anything to the contrary in the foregoing, the obligations of
confidentiality and non-use with respect to any trade secret within such Confidential Information shall survive for so long as such Confidential Information remains protected as a trade secret under Applicable
Law. 

  

	4.2	 Exceptions. The obligations in Section 4.1 (Nondisclosure and Non-Use) shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent evidence: 

 

	 	(a)	 is in the public domain at the time it is disclosed to the Receiving Party hereunder; 

 

	 	(b)	 is known to the Receiving Party or any of its Affiliates at the time of its receipt without bearing any
obligation to keep it confidential; 

  
 -10- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	(c)	 is subsequently disclosed to the Receiving Party or any of its Affiliates on a
non-confidential basis by a Third Party that, to the Receiving Party’s knowledge, is not bound by a duty of confidentiality; 

 

	 	(d)	 is now, or hereafter becomes, through no breach of this Agreement on the part of the Receiving Party or any of
its Affiliates, publicly known or available, either before or after it is disclosed to the Receiving Party; 

  

	 	(e)	 is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates
without the aid, use of, access to, or application of any of the Confidential Information belonging to the Disclosing Party; or 

  

	 	(f)	 is the subject of written permission to disclose provided by the Disclosing Party. 

 

	4.3	 Authorized Disclosure. 

 

	 	(a)	 Permitted Disclosure. Notwithstanding the provisions of Section 4.1 (Nondisclosure and Non-Use), the Receiving Party may disclose Confidential Information belonging to the Disclosing Party in the following instances: (i) filing of Regulatory Materials in order to obtain or maintain MAAs and other
regulatory approvals in its Territory; (ii) complying with Applicable Law or regulation or order of any court or Government Authority, including responding to a subpoena in a Third Party litigation to the extent mandatory; and (iii) to its
Affiliates and (in each case actual or potential) sublicensees, merger, acquisition or other business partners, subcontractors, payors, employees, consultants, agents, and advisors on a
“need-to-know” basis, each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information
that are substantially similar to those set forth in this Article 4 (Confidentiality); or (iv) to (in each case actual or potential) investment bankers, investors, lenders or financial partners, or their respective representatives on a “need-to-know” basis, each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that
are substantially similar to those set forth in this Article 4 (Confidentiality), except that, for all Confidential Information aside from SAS datasets and TMF, the term of such confidentiality agreement may be shorter if in accordance with
industry standards for investment bankers, investors, lenders or financial partners; provided, further, that the Receiving Party shall be liable for their breaches thereto. 

 

	 	(b)	 Notice; Confidential Treatment. If and whenever any Confidential Information is disclosed in accordance
with this Section 4.3 (Authorized Disclosure), such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than
by breach of this Agreement). Notwithstanding the foregoing, if a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Section 4.3(a)(ii), then it shall, except where prohibited by Applicable
Law, (i) give reasonable prior written notice to the other 

  
 -11- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
Party of such disclosure and use not less than the same efforts to secure confidential treatment of or a protective (or similar) order for such Confidential Information as it would to protect its
own Confidential Information from disclosure and (ii) only disclose the minimum amount of Confidential Information reasonably required for the purpose of such disclosure, as advised by legal counsel. 

 

	4.4	 Restricted Disclosure. 

 

	 	(a)	 Notwithstanding any provisions of this Agreement, Urovant shall not disclose (i) the SAS datasets and
programs provided by Kyorin under Section 2.1(b), including any result of statistical analysis or manipulation thereof and (ii) TMF provided by Kyorin under Section 2.1(b), to Government Authorities or any other Third Party other than
a consultant or agent engaged to assist with statistical analysis or manipulation, each of whom prior to disclosure must be bound by obligations of confidentiality and restrictions on use of such Confidential Information that are substantially
similar to those set forth in this Article 4 (Confidentiality), except that Urovant may submit (i) such SAS datasets and programs and TMF to Government Authorities in the Urovant Territory after the date on which Kyorin obtains the
marketing authorization of Vibegron in Japan and (ii) [***]; provided, that Urovant shall be liable for any breach by such consultant or agent of obligations of confidentiality or restrictions on use of the Kyorin Information set forth
in subsection (i) and (ii) above. [***.] 

  

	 	(b)	 Urovant represents and warrants to Kyorin as of the Effective Date that [***.] 

 

	 	(c)	 If Urovant breaches any of its obligations, representations or warranties under subsections (a) and (b)
above and Kyorin incurs damages due to such breach, then Urovant shall, at Kyorin’s option, either (i) compensate Kyorin for its damages [***] or (ii) pay [***] as liquidated damages. [***]. 

ARTICLE 5 
 DISPUTE
RESOLUTION 
  

	5.1	 Dispute Resolution. In the event of any disputes, claims or controversies arising in whole
or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof between the Parties (each, a “Dispute”), the Parties shall first attempt in good faith to resolve such Dispute by
negotiation and consultation between themselves on an informal basis, facilitated by each Party’s Contact Person, for a period of ten (10) Business Days after the date of the receipt of a written notice of such Dispute by a Party. If such
Dispute is not resolved within such ten (10) Business Day period, either Party may, by giving written notice to the other Party, refer the Dispute to the senior executive officer (or his or her delegate) of the other Party for attempted
resolution by good faith negotiation within thirty (30) days after the date of the expiration of such ten (10) Business Day period. Each Party may, in its sole discretion, seek resolution of any and all Disputes that are not resolved under
this Section 5.1 (Dispute Resolution) in accordance with Section 5.2 (Arbitration). 

  

	5.2	 Arbitration. Any unresolved Dispute which was subject to Section 5.1 (Dispute
Resolution) shall be settled by binding arbitration in accordance with the International Chamber of Commerce (ICC) rules of arbitration. Any demand by a Party for arbitration must be made in writing to the other Party. The number of arbitrators
shall be three (3), of whom each Party shall appoint one (1). The two arbitrators so appointed shall select the third and final arbitrator. The place of arbitration shall be Tokyo, Japan if arbitration is requested by Urovant and Basel,
Switzerland if arbitration is requested by Kyorin. The language used in the arbitration proceedings shall be English. The proceedings, including any outcome, shall be confidential. The arbitrators shall render a written opinion setting forth the
findings of fact and conclusions of law. The decision of the arbitrators shall be final and binding upon both Parties absent manifest error. All awards may if necessary be enforced by any court having jurisdiction in the same manner as a judgment in
such court. 

  
 -12- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	5.3	 Injunctive Relief. Notwithstanding the foregoing, in the event of an actual or threatened
breach hereunder, the aggrieved Party may seek equitable relief (including restraining orders, specific performance or other injunctive relief) in any court of competent jurisdiction, without first submitting to the dispute resolution procedures set
forth in Section 5.1 (Dispute Resolution) or Section 5.2 (Arbitration). 

  

	5.4	 Confidentiality. Activities conducted under this Article 5 (Dispute
Resolution) shall be deemed Confidential Information of each of the Parties, and shall be subject to the terms of Article 4 (Confidentiality). 

ARTICLE 6 

INDEMNIFICATION 
  

	6.1	 Indemnification by Urovant. Urovant shall save, defend and hold Kyorin and its
Affiliates and its and their respective directors, officers, employees and agents (each, a “Kyorin Indemnitee”) harmless from and against any and all liabilities, expenses and losses, including reasonable legal expenses and
attorneys’ fees (collectively, “Losses”), to which any Kyorin Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly or indirectly
out of: (a) the negligence or willful misconduct of any Urovant Indemnitee in performing under this Agreement, (b) the breach by Urovant of any warranty, representation, covenant or agreement made by Urovant in this Agreement or
(c) any activities by Urovant or its Affiliates or their respective sublicensees or subcontractors with respect to Vibegron, except, in each case, to the extent such Losses result from clause (a), (b) or (c) of Section 6.2
(Indemnification by Kyorin). 

  

	6.2	 Indemnification by Kyorin. Kyorin shall save, defend and hold Urovant, its
Affiliates, its licensees and their respective directors, officers, employees and agents (each, a “Urovant Indemnitee”) harmless from and against any and all Losses to which any Urovant Indemnitee may become subject as a result of
any claim, demand, action or other proceeding by any Third Party to the extent such Losses arise directly or indirectly out of: (a) the negligence or willful misconduct of any Kyorin Indemnitee in performing under this Agreement, (b) the
breach by Kyorin of any warranty, representation, covenant or agreement made by Kyorin in this Agreement or (c) any activities by Kyorin or its Affiliates or their respective sublicensees or subcontractors with respect to Vibegron, except, in
each case, to the extent such Losses result from clause (a), (b) or (c) of Section 6.1 (Indemnification by Urovant). 

  

	6.3	 Control of Defense. The Party entitled to indemnification under this Article 6
(Indemnification) shall give a written notice to the indemnifying Party of any Losses that may be subject to indemnification promptly after learning of such Losses (provided, however, that any failure or delay to notify shall not excuse any
obligation of the indemnifying Party except to the extent such Party is actually prejudiced thereby), and the indemnifying Party shall assume (and have control over) the defense of such Losses with

  
 -13- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
counsel reasonably satisfactory to the indemnified Party and the indemnified Party shall reasonably cooperate with such defense (at the indemnifying Party’s reasonable expense). If such
defense is assumed by the indemnifying Party with counsel so selected, the indemnifying Party shall not settle any claim with respect to such Losses without obtaining the indemnified Party’s prior written consent (but such consent shall not be
unreasonably withheld or delayed), and shall not be obligated to pay the fees and expenses of any separate counsel retained by the indemnified Party with respect to such Losses. For clarity, the indemnified Party may freely withhold its consent to a
settlement of a claim with respect to Losses if (a) such settlement does not include a complete release from liability of the indemnified Party or if such settlement would involve undertaking an obligation (including the payment of money by an
indemnified Party), (b) would bind or impair the indemnified Party or (c) includes any admission of wrongdoing or that any intellectual property or proprietary right of the indemnified Party or this Agreement is invalid, narrowed in scope or
unenforceable. The indemnified Party shall not settle or compromise any claim for which it is entitled to indemnification without obtaining the prior written consent of the indemnifying Party, unless the indemnifying Party is in breach of its
obligation to defend hereunder. 

 ARTICLE 7 

TERM AND TERMINATION 
  

	7.1	 Term. This Agreement shall become effective on the Effective Date and shall continue for
so long as both Parties (or their sublicensees or Affiliate(s)) are Developing or Commercializing Vibegron, unless otherwise extended or terminated earlier by agreement of the Parties or as set forth in Section 7.2 (Termination for Material
Breach), Section 7.3 (Termination for Change of Control), or Section 7.4 (Termination by Urovant Before Receipt of SAS Dataset). 

  

	7.2	 Termination for Material Breach. Each Party shall have the right to terminate this
Agreement by giving sixty (60) days’ prior written notice to the other Party for the material breach of this Agreement, if such other Party has not cured such material breach within the sixty
(60)-day period after the date of the receipt of such written notice. For clarity, any breach by Urovant of any of its obligations, representation or warranties under Section 4.4(a) and (b) shall be
deemed a material breach of this Agreement, and in such case, this Section 7.2 (Termination for Material Breach) shall apply in addition to Section 4.4(c). Notwithstanding the foregoing, if the allegedly breaching Party notifies the other
Party within such sixty (60)-day period that it disagrees in good faith with such asserted basis for termination, this Agreement shall not terminate unless and until it has been finally determined in
accordance with Article 5 (Dispute Resolution) that the allegedly breaching Party was in material breach with respect to such matter. During the pendency of any such dispute, each Party shall continue to perform its obligations hereunder.

  

	7.3	 Termination for Change of Control. Each Party shall have the right to terminate this
Agreement by giving sixty (60) days’ prior written notice to the other Party if a Change of Control occurs to the other Party. 

  
 -14- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	7.4	 Termination by Urovant Before Receipt of SAS Dataset. Urovant shall have the right to
terminate this Agreement prior to receipt of Kyorin’s SAS dataset, upon written notice to Kyorin. 

  

	7.5	 Effect of Expiration or Termination. 

 

	 	(a)	 Termination for Material Breach. Upon the termination of this Agreement by either Party (the
“Terminating Party”) pursuant to Section 7.2 (Termination for Material Breach): 

  

	 	(i)	 The rights granted by the Terminating Party to the other Party (the “Terminated Party”) under
Sections 2.1 (Share of Information) and 2.2 (Urovant Right of Reference) or 2.3 (Kyorin Right of Reference), as applicable, shall terminate. 

  

	 	(ii)	 The rights granted by the Terminated Party to the Terminating Party under Sections 2.1 (Share of Information)
and 2.2 (Urovant Right of Reference) or 2.3 (Kyorin Right of Reference) shall continue. 

  

	 	(iii)	 The Terminated Party shall promptly, in accordance with the request of the Terminating Party, delete or destroy
(such destruction to be certified in writing by an officer of such Party) all Confidential Information and Regulatory Materials of the Terminating Party; provided, that the Terminated Party may keep one copy of such Confidential Information
for legal archival purposes only subject to the continuing confidentiality and non-use obligations in accordance with Article 4 (Confidentiality). Notwithstanding the foregoing, the Terminated Party shall
not be required to destroy any computer files created during automatic system back up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Terminating Party’s
Confidential Information under this Agreement. 

  

	 	(iv)	 If Kyorin is the Terminating Party, then Kyorin’s rights and Urovant’s obligations under
Section 2.8 (Kyorin Right of First Review and Negotiation) and Section 2.9 (Urovant Change of Control) shall continue for so long as Kyorin’s rights under Section 7.5(a)(ii) continue. 

 

	 	(v)	 If Kyorin is the Terminated Party, then Kyorin’s rights and Urovant’s obligations under
Section 2.8 (Kyorin Right of First Review and Negotiation) and Section 2.9 (Urovant Change of Control) shall terminate. 

  

	 	(b)	 Termination for Change of Control. Upon the termination of this Agreement by either Party pursuant to
Section 7.3 (Termination for Change of Control): 

  

	 	(i)	 The rights of both Parties granted under Sections 2.1 (Share of Information) and 2.2 (Urovant Right of
Reference) or 2.3 (Kyorin Right of Reference) shall terminate. 

  
 -15- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	(ii)	 Each Receiving Party shall promptly, in accordance with the request of the Disclosing Party, delete or destroy
(such destruction to be certified in writing by an officer of such Party) all Confidential Information and Regulatory Materials of such Disclosing Party; provided, that such Receiving Party may keep one copy of such Confidential Information
for legal archival purposes only subject to the continuing confidentiality and non-use obligations in accordance with Article 4 (Confidentiality). Notwithstanding the foregoing, such Receiving Party shall
not be required to destroy any computer files created during automatic system back up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Disclosing Party’s
Confidential Information under this Agreement. 

  

	 	(c)	 Termination by Urovant Before Receipt of SAS Dataset. Upon the termination of this Agreement by Urovant
pursuant to Section 7.4 (Termination by Urovant Before Receipt of SAS Dataset): 

  

	 	(i)	 The rights of both Parties granted under Sections 2.1 (Share of Information) and 2.2 (Urovant Right of
Reference) or 2.3 (Kyorin Right of Reference) shall terminate. 

  

	 	(ii)	 Kyorin’s rights and Urovant’s obligations under Section 2.8 (Kyorin Right of First Review and
Negotiation), Section 2.9 (Urovant Change of Control) and, upon Urovant’s deletion or destruction of CSRs (such deletion or destruction to be certified in writing by an officer of Urovant) if Urovant does not keep one copy of CSRs despite
Section 7.5(c)(iii), Section 4.4 (Restricted Disclosure) shall terminate. 

  

	 	(iii)	 Each Receiving Party shall promptly, in accordance with the request of the Disclosing Party, delete or destroy
(such deletion or destruction to be certified in writing by an officer of such Party) all Confidential Information and Regulatory Materials of such Disclosing Party; provided, that such Receiving Party may keep one copy of such Confidential
Information for legal archival purposes only subject to the continuing confidentiality and non-use obligations in accordance with Article 4 (Confidentiality). Notwithstanding the foregoing, such Receiving
Party shall not be required to destroy any computer files created during automatic system back up that are subsequently stored securely by it and not readily accessible to its employees, consultants, or others who received the Disclosing
Party’s Confidential Information under this Agreement. 

  

	7.6	 Survival. The following provisions of this Agreement shall survive termination:
Article 4 (Confidentiality), Article 5 (Dispute Resolution), Article 6 (Indemnification), Section 7.5 (Effect of Expiration or Termination), Section 7.6 (Survival), and Article 8 (Miscellaneous). Termination or
expiration of this Agreement are neither Party’s exclusive remedy and shall neither relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration nor preclude either
Party from pursuing all rights and remedies it may have hereunder or at law or in equity 

  
 -16- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
with respect to any breach of this Agreement, nor prejudice either Party’s right to obtain performance of any obligation. In the event that, following the effective date of termination under
Section 7.2 (Termination for Material Breach), the Terminating Party fails to comply with the surviving provisions above, the Terminated Party shall have the right to terminate the Terminating Party’s rights under Section 7.5(a)(ii)
by following the procedures set forth in Section 7.2 (Termination for Material Breach). Following such termination, Section 7.5(a)(i) and (iii) shall apply mutatis mutandis (with the formerly Terminating Party deemed to be the
Terminated Party, but for clarity, the formerly Terminated Party shall not be deemed to be the Terminating Party). 

ARTICLE 8 
 MISCELLANEOUS

  

	8.1	 No Implied Licenses. No license or other right is or shall be created or granted hereunder
by implication, estoppel, or otherwise. All rights are or shall be granted only as expressly provided in this Agreement. 

  

	8.2	 Mutual Representations, Warranties and Covenants. Each of the Parties hereby represents
and warrants to the other Party as of the Effective Date and covenants that: 

  

	 	(a)	 Organization. It is a corporation duly organized, validly existing, and in good standing under the laws
of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement. 

  

	 	(b)	 Binding Agreement. This Agreement is a legal and valid obligation binding upon such Party and
enforceable in accordance with its terms. 

  

	 	(c)	 Authorization. The execution, delivery, and performance of this Agreement by such Party have been duly
authorized by all necessary corporate action and do not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law or any order, writ, judgment,
injunction, decree, determination, or award of any court or governmental body, or administrative or other agency presently in effect applicable to such Party. 

 

	 	(d)	 No Inconsistent Obligations. Neither Party is under any obligation, contractual or otherwise, to any
Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder. 

 

	8.3	 No Other Representations or Warranties. NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS
ANY WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT. ANY INFORMATION PROVIDED PURSUANT TO THIS AGREEMENT IS MADE AVAILABLE ON AN “AS IS” BASIS
WITHOUT WARRANTY WITH RESPECT TO 

  
 -17- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
ACCURACY, COMPLETENESS, COMPLIANCE WITH REGULATORY STANDARDS OR REGULATIONS OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED. 

 

	8.4	 Assignment. Neither Party may assign or transfer this Agreement or any rights or
obligations hereunder without obtaining the prior written consent of the other Party, except that each Party may assign its rights and obligations under this Agreement in whole or in part to one or more of its Affiliates without the consent of the
other Party. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 8.4 (Assignment) shall be null, void and of no
legal effect. 

  

	8.5	 Notices. Any notice to be given under this Agreement must be in writing and
delivered either in person, or by (a) air mail (postage prepaid) requiring return receipt, (b) international courier, or (c) e-mail to the Party to be notified at its address(es) given below,
with delivery and read receipts requested, or at any address such Party may designate by a prior written notice to the other Party in accordance with this Section 8.5 (Notices). Notice shall be deemed sufficiently given for all purposes upon:
(i) if by air mail or courier, the date of actual receipt; or (ii) if by e-mail, the date of confirmation of receipt by the intended recipient. Notices shall be sent to: 

 

			
	For Urovant:	  	Urovant Sciences GmbH
		  	Viaduktstrasse 8
		  	4051 Basel
		  	Switzerland
		  	Attention: Sascha Bucher, VP, Head of Global Transactions
		  	Email: sascha.bucher@roivant.com
		
	Copy to:	  	Urovant Sciences, Inc.
		  	320 West 37th Street
		  	5th Floor
		  	New York, NY 10018
		  	Attention: Legal Department
		
	[***]	  	
		
	For Kyorin:	  	Kyorin Pharmaceutical Co., Ltd
		  	6, Kanda Surugadai 4-chome
		  	Chiyoda-ku, Tokyo 101-8311
		  	Japan
		  	Attention: Makoto Yanai, Senior Director, Business Development HQs
		  	Email: makoto.yanai@mb.kyorin-pharm.co.jp

  
 -18- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

			
	Copy to:	  	Kyorin Holdings, Inc.
		  	6, Kanda Surugadai 4-chome
		  	Chiyoda-ku, Tokyo 101-8311
		  	Japan
		  	Attention: Legal Department

  

	8.6	 [***] 

  

	8.7	 Force Majeure. Each Party shall be excused from liability for the failure or delay
in performance of any obligation under this Agreement (other than failure to make payment when due) by reason of any event beyond such Party’s reasonable control including acts of God, fire, flood, explosion, earthquake, pandemic flu, or other
natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty or any other event similar to those enumerated above; provided, that the affected Party shall use commercially reasonable efforts to avoid or remove
such causes of non-performance and to mitigate the effect of such occurrence. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in
performance and provided that the Party has not caused such event(s) to occur. Notice of a Party’s failure or delay in performance due to force majeure must be given to the other Party as promptly as is reasonably practicable after its
occurrence and such Party shall provide the other Party with monthly status updates for the duration of the effect. All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force
majeure. In no event shall any Party be required to prevent or settle any labor disturbance or dispute. 

  

	8.8	 No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly
made for the benefit of any Person other than the Parties and their successors and permitted assigns, except for the Persons expressly entitled to indemnification as provided in Article 6 (Indemnification) and only in accordance with the terms of
Article 6 (Indemnification). 

  

	8.9	 Entire Agreement. This Agreement and the Appendixes attached hereto and made a part
hereof, contain every obligation and understanding between the Parties relating to the subject hereof and merge all prior discussions, negotiations and agreements, including the Letter Agreement, between them, and none of the Parties shall be bound
by any conditions, definitions, understandings, warranties or representations other than as expressly provided or referred to herein. 

  

	8.10	 Severability. If any one or more of the provisions of this Agreement is held to be invalid
or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make
a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable provision such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

 

	8.11	 Waiver and Non-Exclusion of Remedies. Any term or
condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of

  
 -19- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

	 	
the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of
any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law
or otherwise available except as expressly set forth herein. 

  

	8.12	 Relationship of the Parties. It is expressly agreed that the Parties shall be independent
contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action
which shall be binding on the other Party, without obtaining the prior written consent of the other Party to do so. All Persons employed by a Party shall be employees of that Party and not of the other Party and all expenses and obligations incurred
by reason of such employment shall be for the account and expense of such Party. 

  

	8.13	 Construction; Rules of Construction. Interpretation of this Agreement shall be governed by
the following rules of construction: (a) words in the singular shall be held to include the plural and vice versa, and words of one gender shall be held to include the other gender as the context requires; (b) the word
“including” and words of similar import when used in this Agreement shall mean “including without limitation,” unless otherwise specified; (c) the word “or” shall not be exclusive (i.e., it shall be construed to
mean “and/or”), except where the context clearly requires otherwise; (d) the titles and headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement; (e) each of the Parties has participated in the negotiation and drafting of this Agreement and if an ambiguity or question of interpretation should arise, this Agreement shall be construed as if drafted jointly by the Parties and no
presumption or burden of proof shall arise favoring or burdening either Party by virtue of the authorship of any of the provisions in this Agreement or any interim drafts of this Agreement; (f) references to “days” shall mean calendar
days, unless otherwise specified; and (g) a reference to any Person includes such Person’s successors and permitted assigns. 

  

	8.14	 Governing Law. This Agreement was prepared in the English language, which language shall
govern the interpretation of, and any dispute regarding, the terms of this Agreement or the Party’s respective performance hereunder. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be
governed by and construed under the laws of Switzerland, without giving effect to any choice of law principles that would require the application of the laws of a different country. 

 

	8.15	 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each
Party hereto as if they were the original signatures. 

 [remainder of page intentionally left blank] 

  
 -20- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective Date, by
their duly authorized representatives. 
  

									
	Kyorin Pharmaceutical Co., Ltd.	 		 	Urovant Sciences GmbH
					
	By:	 	/s/ Minoru Hogawa	 		 	By:	 	/s/ Sascha Bucher
	Name:	 	Minoru Hogawa	 		 	Name: Sascha Bucher
	Title:	 	 Representative Director
 President &
Chief Executive Officer
	 		 	Title: VP, Head of Global Transactions
		 		 		 	[***]

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 Appendix 1 

Urovant to provide to Kyorin within [***] of Kyorin request 

[***] 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 Appendix 2 

Previously provided to Urovant under the Letter Agreement 

[***] 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 Appendix 3 
 Kyorin
to provide to Urovant within [***] of Effective Date 
 [***] 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 Appendix 4 
 Kyorin
to provide to Urovant at the time specified below, unless otherwise agreed 
 [***] 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 Appendix 5 
 Kyorin
Clinical Trials 
 [***] 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 Appendix 6 
 Kyorin
Non-Clinical Studies 
 [***] 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTEDEX-10.5

 Exhibit 10.5 

EXECUTION VERSION 
 ENZYME SUPPLY
AGREEMENT 
 THIS ENZYME SUPPLY AGREEMENT, including the exhibits attached hereto (the “Agreement”),
effective as of September 01, 2017 (the “Effective Date”), is made and entered into by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California
94063, United States of America (“Codexis”), and Urovant Sciences GmbH, a Swiss corporation, having a place of business at Viaduktstrasse 8, 4051 Basel, Switzerland (“Customer”). Codexis and
Customer each may be referred to herein individually as a “Party,” or collectively as the “Parties.” 

WHEREAS, Codexis has proprietary rights in certain enzymes, chemical synthesis and biocatalysis process technology, and possesses
certain valuable business and/or technical knowledge, information, and/or expertise, relating to enzymatically catalyzed manufacturing processes; 

WHEREAS, Customer is engaged in the business of manufacturing and supplying pharmaceutical ingredients and intermediates thereof and
has proprietary rights in certain compounds, including the Product, methods of manufacturing the Product and methods of use of the Product; 

WHEREAS, Customer is a licensee of certain intellectual property from Merck, Sharp & Dohme Corp.
(“MSD”) relating to the manufacture, sale and distribution of Product in the Territory; 
 WHEREAS, Codexis
desires to supply Codexis Enzyme to Customer, and Customer desires to use such Codexis Enzyme in the manufacture and supply of Product to customers in the Territory, as more fully set forth in this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	1.	 DEFINITIONS 

1.1    “Affiliate” shall mean any entity that is controlled by, controls, or is under
common control with a Party on or after the Effective Date, as the case may be. For purposes of this Section 1.1, the term “control” means (a) direct or indirect ownership of more than fifty percent (50%) of the voting interest
in the entity in question, or more than fifty percent (50%) interest in the income of the entity in question; provided, however, that, if local law requires a minimum percentage of local ownership of greater than fifty percent (50%),
control will be established by direct or indirect beneficial ownership of one hundred percent (100%) of the maximum ownership percentage that may, under local law, be owned by foreign interests, or (b) possession, directly or indirectly, of the
power to direct or cause the direction of management or policies of the entity in question (whether through ownership of securities or other ownership interests, by contract or otherwise). 

  
 -1- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. 

 EXECUTION VERSION 
  

 1.2    “Agency” shall mean any applicable
local, national or supranational government regulatory authority involved in granting approvals for the manufacturing, marketing and/or pricing of Product. “Agencies” is the plural of Agency. 

1.3    “Applicable Law” shall mean all laws, statutes, ordinances, codes, rules, and
regulations that have been enacted by a Government Authority and are in force as of the Effective Date or come into force during the Term, in each case to the extent that the same are applicable to the performance by the Parties of their respective
obligations under this Agreement. 
 1.4    “Calendar Year” shall mean any twelve
(12) consecutive month period commencing on January 1 and ending December 31 during the Term. For example, Calendar Year 2017, for purposes of this Agreement, shall mean the period from January 1, 2017 through
December 31, 2017. 
 1.5    “Claims” shall have the meaning set
forth in Section 10.1. 
 1.6    “Codexis Enzyme” shall mean Codexis’ [***].

 1.7    “Codexis Inventions” shall mean any discovery, invention, contribution, method,
finding or improvement, whether or not patentable, and all related intellectual property, including without limitation patents, trade secrets, and/or know-how, that is conceived, reduced to practice, or
otherwise developed by Codexis or its Affiliates, either solely or jointly with a Third Party, during the Term that relate solely to the Codexis Technology. 

1.8    “Codexis Process” shall mean the process for the transformation of Substrate to
Product using Codexis Enzyme, as covered by those patents and patent applications listed in Exhibit 1.8. 

1.9    “Codexis Technology” shall mean (a) Codexis Enzyme, (b) Codexis Process,
and (c) Codexis Inventions, including, in each case, any intellectual property rights embodied therein. 

1.10    “Commercial Materials” shall have the meaning set forth in
Exhibit 4.1. 
 1.11    “Confidential Information” shall mean any
information of a confidential and/or proprietary nature, including without limitation the data, results, inventories, know-how, processes, machines, methods, developments, compositions of matter, inventions,
invention disclosures, patent applications, proprietary materials and/or techniques, economic information, business or research strategies, purchase orders (and any information included therein), trade secrets, or other information of any type or
kind, and material embodiments thereof, disclosed by a Party to the other Party. 

  
 -2- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 1.12    “Control” shall mean, with respect
to an item, information or intellectual property right, possession of the ability, whether arising by ownership or license, to grant a license or sublicense as provided for herein under such item, information or intellectual property right without
violating the terms of a written agreement with any Third Party. 
 1.13    “Customer
Technology” shall mean intellectual property rights licensed from third parties or developed solely by Customer with respect to (a) the Product and derivatives thereof, (b) the processes to make the Product; and (c) uses
of the Product, including, in each case, any intellectual property rights embodied therein. 

1.14    “Enzyme Specification” shall have the meaning set forth in Section 3.5(e).

 1.15    “Facility” shall mean the facility/facilities of Codexis or its Third Party
Contractor(s) where the Codexis Enzyme are manufactured. 
 1.16    “Firm Order” shall
mean a binding commitment in writing, made by Customer, to purchase a specified amount of Codexis Enzyme from Codexis. 

1.17    “First Health Registration” shall have the meaning set forth in Section 8.3(a)
(License Obligations). 
 1.18    “Government Authority” shall mean any supranational,
national, regional, state or local government, court, governmental agency, authority, board, bureau, instrumentality, regulatory body, or other government entity, including without limitation any of the foregoing that is involved in the granting of
approvals, licenses, registrations, or authorizations. 
 1.19    “Health Registration”
shall mean a New Drug Application or [***] prepared in conformance with applicable Agency regulations for filing with the Agency for marketing authorization of Product. 

1.20    [***] shall mean, with respect to any country in the Territory, [***]. 

1.21    “Pre-Commercial Materials” shall have the
meaning set forth in Exhibit 4.1. 
 1.22    “Product” shall mean
vibegron [***]. 
 1.23    “Quarter” shall mean each of the three consecutive calendar
months ending March 31, June 30, September 30 and December 31. 

1.24    “Substrate” shall mean [***]. 

1.25    “Term” shall have the meaning set forth in Section 9.1 (Term). 

  
 -3- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 1.26    “Territory” shall mean all of the
countries of the world excluding Brunei, Cambodia, Hong Kong, Indonesia, Japan, Korea, Laos, Malaysia, Myanmar, Philippines, Singapore, Taiwan, Thailand and Vietnam. 

1.27    “Third Party” (and with its correlative meaning, “Third
Parties”) shall mean any party other than Codexis, Customer, or an Affiliate of either Codexis or Customer. 
  

	2.	 LICENSE FOR PRODUCT 

2.1    License for Product. Customer represents and warrants to Codexis that it Controls the Product (with
respect to the manufacturing and/or sale of the Product in the Territory) and that it is a licensee of and possesses all required intellectual property rights from MSD relating to the manufacture and sale of the Product in the Territory. If, at any
time, Customer ceases to Control the Product (with respect to the manufacturing and/or sale of the Product in the Territory) or be authorized to manufacture and sell Product in all of the Territory, this Agreement shall terminate. If, at any time,
Customer ceases to Control the Product and be authorized to manufacture and sell Product in any portion of the Territory, then with respect to such portion(s) of the Territory in which Customer ceases to Control the Product or be authorized to
manufacture and sell Product, this Agreement shall terminate 
  

	3.	 ENZYME SUPPLY 

3.1    Codexis Enzyme Supply. Subject to the terms and conditions of this Agreement, Codexis shall supply
Codexis Enzyme on a non-exclusive basis to Customer, and Customer shall purchase from Codexis all of its requirements for Codexis Enzyme, for use in the manufacture of Product by Customer for sale by or on
behalf of Customer of such Product in the Territory during the Term. [***]. 
 3.2    Terms and
Conditions. All supply of Codexis Enzyme by Codexis to Customer shall be subject to the terms and conditions of this Agreement. Any terms of any Purchase Order or acknowledgement given or received which are inconsistent with this Agreement given
by either Party shall have no effect, and such terms are hereby excluded and rejected. 
 3.3    Restricted
Rights. All Codexis Enzyme transferred to Customer under this Agreement are and shall be solely used for the manufacture of Product by Customer for sale by or on behalf of Customer (whether as Product or as incorporated in a formulated drug
product) in the Territory in accordance with the terms and conditions of this Agreement. Product manufactured by Customer using Codexis Enzyme and pursuant to the license granted herein may not be resold by or for Customer with intended use or
distribution (whether as Product or as incorporated in a formulated drug product) outside of the Territory. Any distribution, use, or other exploitation of Codexis Enzyme not in accordance with this Agreement shall be considered to be unlicensed and
are hereby 

  
 -4- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 
prohibited. Customer shall not transfer any Codexis Enzyme to any Third Party (except to a contract manufacturing organization using Codexis Enzyme to manufacture Product solely by or for
Customer for sale by or on behalf of Customer in the Territory, in which event Customer shall ensure that such contract manufacturing organization complies with Customer’s obligations under this Section 3.3 (Restricted Rights),
Section 3.9 (Use of Codexis Enzymes, Section 8.1(a) (Ownership by Codexis) and Article 6 (CONFIDENTIALITY). Customer shall not manufacture Codexis Enzyme or acquire Codexis Enzyme from any Third Party. 

3.4    Forecasts. Within [***] at the beginning of each Quarter during the Term, Customer shall provide
Codexis in writing (e-mail is acceptable) a good faith forecast reflecting Customer’s requirements, if any, for Codexis Enzyme for each of the following [***] by setting forth the quantities of Codexis
Enzyme to be supplied, broken down by Quarter. All projected order dates, quantities and shipping dates set forth in the forecasts delivered pursuant to this Section 3.4 shall be binding on Customer in respect of the requirements set forth for
the [***] immediately following the delivery of each such forecast. 
 3.5    Orders. 

(a)    Purchase Orders. At least [***] prior to the beginning of each Quarter during the Term, Customer
shall place a Firm Order for its requirements of Codexis Substance for such Quarter. Customer may also place a Firm Order at any time during the Term of this Agreement; provided, that such Firm Order is submitted at least [***] prior to the
earliest delivery date set forth in such Firm Order. Each Firm Order shall specify the following: 
  

	 	1.	 Quantity of Codexis Enzyme ordered; 

 

	 	2.	 The price of the Codexis Enzyme ordered per Exhibit 4.1; 

 

	 	3.	 The required delivery date(s); 

 

	 	4.	 The ship-to address; 

 

	 	5.	 The specific packaging amount; 

 

	 	6.	 Shipping conditions. 

(b)    Subject to the terms and conditions of this Agreement, Codexis shall accept such Firm Orders from Customer
for each Codexis Enzyme; provided, that Codexis shall not be obligated to accept a Firm Order for Codexis Enzyme for any particular Quarter to the extent that the quantity of Codexis Enzyme ordered for delivery in such Quarter exceeds [***]
of the quantity of Codexis Enzyme forecasted for such month in accordance with Section 3.4 (Forecasts); provided, however, that Codexis shall use commercially reasonable efforts to fulfill orders for such excess quantities from
available supplies, taking into account Codexis’ own use, distribution and other obligations. Codexis shall communicate to Customer any potential manufacturing or supply challenges of which it is aware at the time of receipt of the Firm Order,
which are reasonably expected to impact Codexis’ ability to fulfill such Firm Order. 

  
 -5- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 (c)    Minimum Order Quantities. Each Firm Order shall be
for the minimum purchase quantity(ies) agreed upon between Codexis and Customer with respect to a Calendar Year as agreed upon in accordance with Exhibit 4.1. 

(d)    Form of Order. All Firm Orders shall be governed by the terms and conditions of this Agreement and
any term or condition set forth in a Firm Order that would materially amend or supplement the terms and conditions of this Agreement is rejected and without effect. All of Customer’s orders for Codexis Enzyme shall be made pursuant to such
written Firm Order form and shall provide for shipment in compliance with Section 3.6 (Delivery and Storage of Codexis Enzymes). Codexis shall promptly notify Customer of its acceptance or rejection of a Firm Order, and shall use commercially
reasonable efforts to do so within [***] from receipt of such Firm Order. 
 (e)    Enzyme Specification.
For Codexis Enzyme that is being supplied to Customer for manufacture of pre-commercial quantities of Product, the [***] Certificate of Analysis attached as Exhibit 3.5(d) shall apply but is
not guaranteed. Prior to the supply of Codexis Enzyme that will be used in the manufacture of Product intended to be sold commercially, the Parties will agree in good faith on final specifications for the Codexis Enzyme to be delivered and shall
attach such final specifications as a replacement Exhibit 3.5(d) (the “Enzyme Specification”). The Parties may amend the Enzyme Specification for Codexis Enzyme hereunder from time to time by mutual written
agreement. Codexis Enzyme shall be manufactured in accordance with appropriate quality controls, as may be mutually agreed upon by the Parties in a separate written Quality Agreement. 

3.6    Delivery and Storage of Codexis Enzyme. Subject to Section 3.5 (Orders), Codexis shall deliver
to Customer the amount of Codexis Enzyme specified in each Firm Order no later than the date(s) specified therein. All Codexis Enzyme shall be shipped by Codexis [***] (Incoterms 2010) at [***] (or such [***] referenced in Section 3.11
(Supply)), and risk of loss shall pass to Customer upon such delivery. Codexis shall ship Codexis Enzyme under appropriate packaging and storage conditions. Codexis shall provide any documentation required for shipment of Codexis Enzyme (e.g. MSDS,
COA for each batch, and shelf life/retesting period for such batch). Customer shall store, handle and maintain the Codexis Enzyme in accordance with storage instructions as determined by Codexis [***], which storage instructions may be amended from
time to time by Codexis in writing. Customer shall bear any and all costs from failure to comply with such storage instructions, including without limitation any payments required for additional quantities of Codexis Enzyme purchased by Customer due
to such failure. 
 3.7    Inspection. Prior to shipment of any Codexis Enzyme, Codexis and/or any Third
Party referenced in Section 3.11 (Supply) shall test and inspect such shipment to ensure compliance with the applicable Enzyme Specification. Upon receipt of shipment of Codexis Enzyme, Customer shall, either directly or through a contract
manufacturing organization, inspect such Codexis Enzyme for compliance with the Enzyme Specification for such Codexis Enzyme corresponding to such shipment. Customer shall inform Codexis of the result of the inspection, including any claim with
respect to all or part of a shipment, 

  
 -6- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 
in writing within [***] after the delivery of such shipment of Codexis Enzyme. In the event that Codexis receives a written notice of claim from Customer, which notice must include sufficient
detail identifying the basis for claim, the Parties shall determine if such claim is proper pursuant to the dispute resolution mechanism set forth in Section 3.8 (Disputes) and shall enter into good faith discussions regarding supply of
replacement quantities of Codexis Enzyme during the dispute resolution process. If Customer fails to notify Codexis in writing of a claim within such [***] period, Customer’s right to submit a claim for the shipment for any basis that would
have been discoverable through an inspection will be deemed to have been waived, notwithstanding any right of Customer to submit a claim to Codexis in connection with latent defects. 

3.8    Disputes. If Codexis disputes Customer’s conclusion to submit a claim with respect to all or
part of any shipment of any Codexis Enzyme as set forth in Section 3.7 (Inspection), Codexis shall notify Customer within [***] after receipt of Customer’s written notice of such rejection. Such dispute shall be resolved by a Third Party
within [***] of such notice by Codexis. Such Third Party shall have expertise in the area of biocatalysis, the identity of whom shall be mutually agreed upon by the Parties, and the appointment of whom shall not be unreasonably delayed or
conditioned by either Party. The determination of such Third Party with respect to all or part of any shipment of any Codexis Enzyme shall be final and binding upon the Parties. The Third Party’s scope of review and decision shall be limited to
the claim with respect to the shipment or part thereof, and Codexis’ responses thereto. For the avoidance of doubt, if such Third Party determines that the reasons given by Customer in submitting a claim with respect to the shipment or part
thereof were: (x) proper, then at Codexis’ election, Codexis shall replace such shipment or provide a full refund or credit, and (y) not proper, then no refund or credit shall be due to Customer. The fees and expenses of such Third
Party shall be paid by [***.] Each of Codexis and Customer shall bear their own fees and expenses, including and legal or consultant fees, incurred under this Section 3.8. 

  
 -7- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 3.9    Use of Codexis Enzymes. Except as expressly set
forth in this Agreement, Customer will not, and will not allow any Third Party to, without the prior written consent of Codexis, (a) extract information from, reverse engineer, deconstruct, disassemble, sequence or in any way determine, or
attempt to extract information from, reverse engineer, deconstruct, disassemble, sequence or in any way determine, the biological, chemical or physical structure or composition of any of the Codexis Enzyme or its components; (b) copy, alter,
immobilize, stabilize, add to, alter, modify or otherwise design or create any derivative of Codexis Enzyme or its components; or (c) transfer any Codexis Enzyme or its respective components, or sequence information pertaining thereto, to a
Third Party (except as expressly provided for under Section 3.3 (Restricted Rights) or Section 8.2 (License to Codexis Technology)) or otherwise sublicense or subcontract any of its rights or obligations under this Agreement to any Third
Party. This Agreement does not permit Customer to use the Codexis Enzyme to treat human subjects. For the avoidance of doubt and without limiting any other remedies Codexis may have, to the extent Customer breaches this Section 3.9, Customer
acknowledges and agrees that Codexis owns any and all intellectual property rights that arise from such breach and Customer hereby exclusively assigns to Codexis all right, title and interest in, to and under such intellectual property that Customer
has or may thereafter acquire as a result of such breach. Customer hereby agrees to take or cause to be taken all actions as Codexis deems necessary or desirable in order for Codexis to obtain the full benefits of the assignment described in the
immediately preceding sentence and the transactions contemplated thereby. 
 3.10    Third Party
Contractors. Codexis shall have the right at any time to satisfy its supply obligations to Customer under this Agreement either in whole or in part through arrangements with Third Parties engaged to perform services or supply facilities or goods
in connection with the manufacture, testing, and/or packaging of Codexis Enzyme; provided, that Codexis shall remain responsible for the actions of such Third Parties and for compliance with its obligations under this Agreement. 

3.11    Supply. 

(a)    Efforts by Codexis. Codexis shall use all commercially reasonable efforts to supply Codexis Enzyme in
accordance with this Article 3; provided, however, that if Codexis encounters any issues in respect of supply or delivery, including but not limited to feasibility issues or scale-up issues,
Codexis shall notify Customer and [***]. 
 (b)    [***] 

3.12    Relationship. As between the Parties, Customer shall be solely responsible for (i) the
production of Product using Codexis Enzyme, (ii) converting Substrate to Product using Customer’s technology, and (iii) distributing, selling and marketing Product in the Territory. 

  
 -8- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

	4.	 PAYMENT; TAXES 

4.1    Pricing. Customer shall pay Codexis for Codexis Enzyme delivered hereunder as established in
accordance with Exhibit 4.1 of this Agreement. In addition, Customer shall pay any and all insurance, shipment, taxes (as further described in Section 4.4 (Taxes)) or other costs incident to the transfer or shipment of the
Codexis Enzyme. 
 4.2    Invoicing. All invoices shall be sent to Customer’s address for notices
hereunder or such other address as designated by Customer in writing, and each such invoice shall state Customer’s aggregate and unit prices for the Codexis Enzyme, and shall separately itemize any insurance, taxes or other costs incident to
the transfer or shipment initially paid by Codexis but to be borne by Customer hereunder. In the event of any discrepancy, Customer shall inform Codexis in writing within [***] of receipt of a particular shipment, specifying the shipment, the Firm
Order number, and the exact nature of the discrepancy between the order and the shipment, or the exact nature of the discrepancy in the shipping or other charges, as applicable, otherwise such shipment and applicable charges shall be deemed correct.

 4.3    Payment. Customer shall make full payment to Codexis for all Codexis Enzyme shipped hereunder no
later than [***] from the date of Codexis’ invoice. Any payment under the terms and conditions of this Agreement made after such [***] period shall bear compounding interest beginning one (1) day after the expiration of such [***] period
and shall continue to accrue such interest until such payment is made at a rate equal to the [***]. 

4.4    Taxes. Customer shall be responsible for all federal, state and local taxes, or charges in lieu of
taxes, now or hereafter imposed on the sale or use of the Codexis Enzyme, except for income or other similar taxes imposed on Codexis. Any taxes for which Customer is responsible hereunder shall be charged to Customer and shall be in addition to the
prices set forth in this Article 4 (PAYMENT; TAXES). 
 4.5    Method. An payments made under this
Agreement shall be made by direct wire transfer of United States Dollars in immediately available funds in the requisite amount to such bank account as Codexis may from time to time designate by written notice to Customer. 

 

	5.	 GOVERNMENTAL LAW AND REGULATIONS 

5.1    Applicable Law. Codexis’ and Customer’s obligations hereunder shall be subject to all
Applicable Law. Codexis shall secure such permits and licenses necessary, at its sole expense, for the manufacture and sale of Codexis Enzyme hereunder, unless otherwise agreed by the Parties in writing. 

5.2    Regulatory Filings. As between the Parties, Customer and its Affiliates will be responsible for
filing any regulatory approval application in connection with Product, at their own cost. 

  
 -9- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 5.3    Records. Codexis shall maintain complete, true, and
accurate books, records, test and laboratory data, reports, and all other information relating to Codexis Enzymes, including the manufacturing data and technical records pertaining to the methods, facilities, and equipment used for processing, in
accordance with Applicable Laws and as is reasonably necessary to support regulatory filings by Customer with respect to the Product. Codexis shall store all such records and information for a period of at least [***] from the relevant Codexis
Enzyme manufacturing date or longer if required under Applicable Laws, after which date Codexis may dispose of such records upon providing reasonable prior written notice of such destruction to allow Customer to request such records. 

5.4    Regulatory Obligations. Customer shall be solely responsible for preparation and submission of
applications to Agencies regarding the Product. Customer will advise Codexis of document requirements in support of such applications by Customer. Codexis will, at Customer’s expense at Codexis’ then-current rates agreed upon by the
Parties, use its commercially reasonable efforts to provide documents and additional information needed for such applications, and to cooperate with and assist Customer in preparation and submission of such applications to the FDA (and other
Agencies, as appropriate). All such applications to Agencies and related filings by Customer shall be the sole and exclusive property of Customer, as applicable. Customer shall be solely responsible for all contacts and communications with any
Agencies with respect to all matters relating to the Product. At the request of Customer, Codexis shall make appropriate personnel reasonably available for meetings with Agencies related to manufacturing of Codexis Enzymes and the related processing
of the Product. 
 5.5    Regulatory Notifications. Codexis shall notify Customer immediately, and in no
event later than [***], after receiving any contact or communication from any Regulatory Authority that in any way relates to the Products. Codexis shall advise Customer no later than the next day that is not a Saturday, Sunday, or federal or state
holiday if an authorized agent of any Agencies or any other regulatory body plans to visit the Facility solely in relation to the Products for Customer, and/or makes an inquiry regarding manufacturing of Codexis Enzymes for use in processing
Products for Customer or regarding any part of the Facility that is used in manufacturing of Codexis Enzymes for use in processing of Products for Customer. Customer shall have the right to be present at any visit relating to Products for Customer
and to review in advance and comment on any response to the communication or investigation submitted by Codexis. Codexis shall cooperate fully with such Regulatory Authority and with Customer in providing the information needed for any such
communication. Codexis shall provide to Customer copies of any document delivered by such Regulatory Authority or regulatory body as a result of such visit. If an authorized agent of any Regulatory Authority or any other regulatory body visits the
Facility in connection with another product or another part of the Facility and such visit results in a finding or other action that could materially and adversely affect Codexis’ production of Codexis Enzyme under this Agreement, then Codexis
shall notify Customer as soon as practicable and shall provide Customer with information concerning Codexis’ response to such finding or action. Customer shall retain the right to amend Codexis’ response to a Regulatory Authority solely in
relation to the Product. 

  
 -10- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 5.6    Audits. During the Term and during the period in
which Codexis is supplying the Codexis Enzymes, Customer or its authorized representatives reasonably acceptable to Codexis at Customer’s cost for the purposes of audit may visit the Facilities of Codexis or its Third Party Contractors where
the Codexis Enzymes are being manufactured, during normal business hours. The detailed scope of audit shall be communicated to Codexis at least [***] prior to the requested date of audit and the Parties shall work in good faith to schedule a
mutually agreeable date for such audit. Any such audit shall be conducted in accordance with Codexis’ then-current policies and without material disruption to Codexis’ or Codexis’ Third Party Contractor activities. Customer shall be
entitled to conduct an audit hereunder once in any [***] period during the term of this Agreement, upon reasonable notice during regular business hours for a period not to exceed [***]; provided, however, that Customer shall be entitled to conduct
audits following issuance of reports delivered by Agencies to Codexis pertaining to manufacturing of Codexis Enzymes for use in processing Products for Customer or the occurrence of other events which are likely to adversely affect Customer’s
processing of Products as frequently as requested by Customer at reasonable times and for reasonable duration (which may not exceed [***]) until Codexis has corrected such deficiencies. Upon request, Customer may conduct additional audits, provided
that Customer shall reimburse Codexis for reasonable time and expenses incurred by Codexis in connection with such audits. 
  

	6.	 CONFIDENTIALITY 

6.1    In General. In connection with this Agreement each Party may provide to the other Party, Confidential
Information. Codexis Technology shall constitute the Confidential Information of Codexis. 
 6.2    Non-Disclosure and Non-Use. The receiving Party shall maintain the Confidential Information of the disclosing Party in confidence, shall not disclose such Confidential
Information to any Third Party, and shall not use such Confidential Information for any purpose except as expressly permitted under the terms and conditions of this Agreement. Notwithstanding the previous sentence, the receiving Party may disclose
the Confidential Information of the disclosing Party solely on a “need to know basis” to its Affiliates and its officers, directors, employees, advisors, legal counsel, contractors and agents, and independent legal counsel, each of whom
prior to disclosure must he hound by obligations of nondisclosure and non-use no less restrictive than the obligations set forth in this Article 6 (CONFIDENTIALITY); provided, however, that,
in each of the above situations, the receiving Party shall remain responsible for any failure by any person or entity who receives Confidential Information pursuant to this Section 6.2 to treat such Confidential Information as required under
this Article 6 (CONFIDENTIALITY). The receiving Party shall take the same degree of care that the receiving Party uses to protect its own confidential and proprietary information of a similar nature and importance, but in no event shall such
care be less than reasonable care. 

  
 -11- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 6.3    Exceptions. The obligations of non-disclosure and non-use under Section 6.2 (Non-Disclosure and Non-Use) will not apply
as to particular Confidential Information of a disclosing Party to the extent that such Confidential Information: (a) is at the time of receipt, or thereafter becomes, through no fault of the receiving Party or its Affiliates, published or
publicly known or available; (b) is known by the receiving Party or its Affiliates at the time of receiving such information, as evidenced by competent records; (c) is hereafter furnished to the receiving Party or its Affiliates by a Third
Party without breach of a duty to the disclosing Party; or (d) is independently discovered or developed by the receiving Party or its Affiliates without use of, application of, access to, or reference to Confidential Information of the
disclosing Party, as evidenced by competent records. 
 6.4    Disclosure Required by Law. Disclosure of
Confidential Information shall not be precluded if such disclosure (a) is in response to a valid order, or required under the regulations, of a court or other governmental body; or (b) is required by Applicable Law; provided,
however, that the receiving Party, to the extent practicable, first has given reasonable prior notice to the disclosing Party and at the disclosing Party’s request, the receiving Party cooperates with the disclosing Party’s efforts,
as applicable, to obtain a protective order limiting the extent of such disclosure and requiring that the Confidential Information so disclosed be used only for the purposes for which such order was issued or as required by such Applicable Law. Any
disclosure made pursuant to this Section 6.4 shall not affect the confidential nature of the disclosed Confidential Information (except to the extent the disclosure was made publicly available, such as but not limited to filings with the United
States Securities and Exchange Commission, in which case such disclosed Confidential Information shall no longer be deemed confidential). 

6.5    Remedies. The receiving Party agrees that its obligations under this Article 6 (CONFIDENTIALITY) are
necessary and reasonable to protect the disclosing Party’s business interests and that the unauthorized disclosure or use of Confidential Information of the disclosing Party will cause irreparable harm and significant injury, the degree of
which may be difficult to ascertain. The receiving Party further acknowledges and agrees that in the event of any actual or threatened breach of this Article 6 (CONFIDENTIALITY), the disclosing Party may have no adequate remedy at law and,
accordingly, that the disclosing Party will have the right to seek an immediate injunction, without an obligation to post a bond or any similar security, enjoining any breach or threatened breach of this Article 6 (CONFIDENTIALITY), as well as the
right to pursue any and all other rights and remedies available at law or in equity for such breach or threatened breach. 

6.6    Agreement Terms; Press Release. The existence of, and the terms and conditions of, this Agreement
shall be Confidential Information of each of the Parties, and subject to the terms of this Article 6 (CONFIDENTIALITY); provided, however, that (a) each Party may disclose this Agreement, in confidence, (i) to [***],
(ii) to legal, scientific, 

  
 -12- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 
regulatory and financial advisors and (iii) in connection with any proposed or actual transactions involving the disclosing Party in the form of mergers, offerings, acquisitions, fundings
and investments; and (b) each Party may disclose this Agreement, in its entirety or with portions redacted, as may be required by Applicable Law. Notwithstanding the foregoing, upon or after the execution of this Agreement, the Parties may:
(c) issue a press release relating generally to their entry into this Agreement, provided, however, that such press release has been agreed to by both Parties prior to issuance; and (d) list the other Party’s name and/or
logo on its website or in promotional materials, and may otherwise disclose that the other Party is a contracting party of such Party. 

6.7    Survival. All obligations of non-disclosure and non-use imposed pursuant to the terms and conditions of this Article 6 (CONFIDENTIALITY) shall survive expiration or termination of this Agreement and continue in full force and effect for a period of [***]
after the effective date of such expiration or such termination. 
  

	7.	 REPRESENTATIONS AND WARRANTIES 

7.1    Representations by Each Party. Each Party represents and warrants that as of the Effective Date:
(a) it is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has MI corporate power and authority to enter into this Agreement; (b) it has taken all corporate actions necessary to authorize the
execution and delivery of this Agreement and the performance of its obligations under this Agreement; and (c) the performance of its obligations under this Agreement do not conflict with, or constitute a default under, its charter documents,
any contractual obligation of such Party or any court order. 
 7.2    Disclaimer of Warranties. EXCEPT AS
SPECIFICALLY SET FORTH IN THIS ARTICLE 7 (REPRESENTATIONS AND WARRANTIES), NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, ANY WARRANTY OF FITNESS FOR
A PARTICULAR PURPOSE OR USE, OR ANY OTHER SIMILAR STATUTORY WARRANTY. EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES. 
  

	8.	 INTELLECTUAL PROPERTY 

8.1    (a) Ownership by Codexis. As between the Parties, subject only to the license set forth in
Section 8.2 (License to Codexis Technology), Codexis shall retain and own all right, title and interest in, to and under the Codexis Technology, and Codexis shall have the right, but not the obligation, to file applications for, and to control
the prosecution and maintenance of, the Codexis Technology and to enforce all rights therein. For the avoidance of doubt, Codexis has no rights to Customer Technology. 

(b)    Ownership by Customer. As between the Parties, Customer shall retain and own all right, title and
interest in, to and under the Customer Technology, and 

  
 -13- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 
Customer shall have the right, but not the obligation, to file applications for, and to control the prosecution and maintenance of, the Customer Technology and to enforce all rights therein. For
the avoidance of doubt, Customer has no rights to improve or modify the Codexis Technology. 
 8.2    License
to Codexis Technology. Subject to the terms and conditions of this Agreement, Codexis hereby grants to Customer a non-exclusive, non-transferrable, non-sublicensable (except as provided below), worldwide license under the Codexis Technology to use and import (but not to make, have made, improve, have improved, modify, have modified, sell, or have sold) Codexis
Enzyme in order to make, have made, use, import, sell and have sold Product in the Territory, This license does not grant Customer any rights under Codexis Technology to use and import Codexis Enzyme in order to make, have made, use, import, sell
and have sold Product (whether as Product or as a formulated drug product) for resale by third parties (including, without limitation, [***]) for sale outside of the Territory. Until the satisfaction by Customer of all of its obligations under
Section 8.3 (License Obligations), the license shall not be transferable, and shall not be sub-licensable except: a) to Affiliates of Customer and to contract manufacturing organizations manufacturing
Product for Customer and its Affiliates; and, b) with regard to the Product formulated as a drug product, to third parties conducting clinical research and/or drug product testing on behalf of the Customer and/or its Affiliates that is necessary for
the regulatory approval in the Territory. After the satisfaction by Customer of all of its obligations under Section 8.3 (License Obligations), the license shall be fully transferrable to a successor to Customer’s rights under this
Agreement and its agreement with MSD relating to the Product and sublicensable. 
 8.3    License
Obligations. In consideration for the license granted by Codexis under Section 8.2 (License to Codexis Technology), Customer agrees to the following payment and purchase obligations: 

(a)    Upon Customer receiving the first approval of a Health Registration for Product in any of the United States,
Europe or Canada (“First Health Registration”), Customer shall pay Codexis a one-time, non-refundable,
non-creditable milestone payment of US$500,000. Customer shall notify Codexis in writing of Customer’s receipt of such First Health Registration, and Codexis shall invoice Customer for such milestone
payment. Such payment shall be made by Customer to Codexis within [***] from the date of such invoice from Codexis. 

(b)    [***.] 

(c)    [***.] 

8.4    No Other Rights. Except for the rights expressly granted in this Agreement, no right, title or
interest of any nature whatsoever is or shall be granted whether as a result of sale or transfer, by implication, estoppels, reliance or otherwise, with respect to the Codexis Technology. All rights with respect to Codexis Technology that are not
specifically granted in this Agreement are reserved to Codexis. 

  
 -14- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

	9.	 TERM AND TERMINATION 

9.1    Term. The term of this Agreement shall commence on the Effective Date through six (6) years from
the date of First Health Registration, unless earlier terminated in accordance with Sections 2.1 (License for Product), 9.2 (Termination for Convenience), 9.3 (Termination for Cause) or 9.4 (Termination for Insolvency) (the
“Term”), 
 9.2    Termination for Convenience. 

(a)    At any time after the Effective Date, but before the date of First Health Registration, Customer may
terminate this Agreement upon written notice to Codexis. 
 (b)    At any time (1) on or after the date of
First Health Registration and (ii) the satisfaction by Customer of all of its obligations under Section 8.3 (License Obligations), Customer may terminate this Agreement upon written notice to Codexis. 

9.3    Termination for Cause. Either Party may terminate this Agreement upon sixty (60) days written
notice to the other Party if the other Party materially breaches any obligation set forth herein, which breach has not been cured within sixty (60) days after receipt of written notice of such breach from the
non-breaching Party, or within such additional cure period as the non-breaching Party may so authorize in writing. in the event of a
non-curable breach, the non-breaching Party shall be entitled, in the non-breaching Party’s sole discretion, to immediately
terminate this Agreement in its entirety. A failure by Customer to make payment hereunder shall be considered a material breach unless cured within [***] of receipt of written notice of such non-payment. 

9.4    Termination for Insolvency. To the extent permitted under Applicable Law, a Party may terminate this
Agreement upon thirty (30) days written notice to the other Party if the other Party becomes insolvent, makes a general assignment for the benefit of creditors, files a voluntary petition in bankruptcy, suffers or permits the appointment of a
receiver for its business or assets, becomes subject to any proceeding under any bankruptcy or any insolvency law, whether domestic or foreign, or has wound up or liquidated its business voluntarily or otherwise. 

9.5    Consequences of Expiration or Termination. 

(a)    Licenses. Upon expiration or termination of this Agreement by either Party for any reason, the
license granted under Section 8.2 shall terminate and Customer shall cease use of any and all Codexis Technology. 

(b)    Return of Materials. Upon expiration or termination of this Agreement by either Party for any reason,
each Party shall promptly return, or destroy and provide written certification of such destruction by a duly authorized officer of such Party, 

  
 -15- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 
any and all Confidential Information of the other Party in such first Party’s possession or control at the time of such expiration or termination and Customer shall promptly return to all
unused supplies of Codexis Enzyme, [***]. 
 (c)    Accrued Liability. Expiration or termination of this
Agreement for any reason shall not release either Party hereto from any liability which at the time of such termination has already accrued to the other Party prior to such time. Such expiration or termination will not relieve a Party from accrued
payment obligations or from obligations which are expressly indicated in this Agreement to survive expiration or termination of this Agreement. 

9.6    Survival. In addition to any sections of this Agreement which by their terms survive expiration or
termination of this Agreement, the following Articles and Sections of this Agreement shall survive its expiration or termination: Articles 1 (DEFINITIONS), 4 (PAYMENT; TAXES), 5 (GOVERNMENTAL LAW AND REGULATIONS),
6 (CONFIDENTIALITY), 10 (INDEMNIFICATION) and 11 (MISCELLANEOUS), and Sections 3.2 (Terms and Conditions), 3.3 (Restricted Rights), 3.8 (Disputes) (if applicable), 3.9 (Use of Codexis Enzyme),
3.12 (Relationship), 7.2 (Disclaimer of Warranties), 8.1 (Ownership of Codexis), 8.4 (No Other Rights), 9.4 (Termination for Insolvency) and 9.5 (Consequences of Expiration or Termination). All obligations to make
payments to Codexis shall survive expiration or termination of this Agreement. 
  

	10.	 INDEMNIFICATION 

10.1    Indemnification by Codexis. Codexis shall indemnify, defend, and hold Customer, its
directors, officers, employees, agents, advisors, contractors and Affiliates harmless from and against all Third Party claims, demands, damages, liabilities, losses, costs, and expenses, including without limitation attorney’s fees
(collectively, “Claims”) in connection with or arising from (a) a breach by Codexis of any of its representations, warranties or obligations under this Agreement, or (b) any negligence or willful misconduct of Codexis in the
performance of its obligations under this Agreement; provided, however, that Codexis’ indemnification obligations under this Section 10.1 shall not apply to the extent such Claims are solely the responsibility of Customer under
Section 10.2 (Indemnification by Customer). 
 10.2    Indemnification by Customer. Customer shall
indemnify, defend, and hold Codexis, its directors, officers, employees, agents, and Affiliates harmless from and against all Claims in connection with or arising from (a) a breach by Customer of their representations, warranties or obligations
under this Agreement, or (b) any negligence or willful misconduct by Customer, or (c) product liability related to the use of any Product; provided, however, that Customer’s indemnification obligations under this Section 10.2
shall not apply to the extent such Claims are solely the responsibility of Codexis under Section 10.1 (Indemnification by Codexis). 

10.3    Insurance. Customer agrees to carry insurance in coverage and amounts reasonable and customary for a
company of similar size and in the same industry as Customer. Codexis agrees to carry insurance in coverage and amounts reasonable and customary for a company of similar size and in the same industry as Customer. 

 

	11.	 MISCELLANEOUS 

11.1    Further Assurances. From time to time on and after the Effective Date, each Party shall at the
reasonable request of the other Party: (a) deliver to the other Party such records, data, or other documents; (b) execute, and deliver or cause to be delivered, all assignments, consents, documents or further instruments of transfer or
license; and (c) take or cause to be taken all other actions as such other Party may reasonably deem necessary or desirable in order for such Party to obtain the full benefits of this Agreement and the transactions contemplated hereby; each to
the extent as required under the provisions of this Agreement. 
 11.2    Limitation of Liability. EXCEPT
FOR BREACHES OF ARTICLE 6 (CONFIDENTIALITY), SECTION 3.10 (Third Party Contractors) OR 

  
 -16- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 
INDEMNIFICATION PURSUANT TO ARTICLE 10 (INDEMNIFICATION), IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES OF THE OTHER
PARTY ARISING OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, WHETHER FORESEEABLE OR NOT. FURTHERMORE, IN NO EVENT SHALL CODEXIS BE LIABLE TO CUSTOMER FOR ANY CLAIM FOR DAMAGES CUSTOMER SUFFERS UNDER THIS
AGREEMENT IN AN AMOUNT EXCEEDING TWO TIMES THE AGGREGATE AMOUNT OF THE PAYMENTS MADE BY OR DUE FROM CUSTOMER TO CODEXIS DURING THE TWELVE (12)-MONTH PERIOD IMMEDIATELY PRECEDING THE DATE OF THE APPLICABLE BREACH UNDER THIS AGREEMENT, PROVIDED THAT
NOTHING HEREIN SHALL BE APPLICABLE TO ACTS OF GROSS NEGLIGENCE, INTENTIONAL BREACH OF THE AGREEMENT OR WILLFUL MISCONDUCT, 

11.3    Governing Law. This Agreement shall be governed by, and construed and interpreted in accordance
with, the internal laws of the State of New York, without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of New York to the rights and duties of the Parties. The
Parties exclusively agree to resolve all disputes arising out of, relating to or in connection with this Agreement by arbitration conducted under the then-existing Commercial Arbitration Rules of the American Arbitration Association
(“AAA”). The arbitration will be conducted in New York, New York, USA before a single, neutral arbitrator chosen by mutual agreement of the Parties or, failing that agreement, within [***] after written notice demanding
arbitration, by the AAA. Any award rendered by the arbitrator will be final, conclusive and binding upon the Parties, and judgment thereon may be entered and enforced in any court of competent jurisdiction. The arbitrator shall determine the claim
of the Parties and render a final award in accordance with the substantive law of the State of New York, excluding the conflicts provisions of such law, and shall apply the New York Rules of Evidence. Nothing in this Agreement shall be deemed as
preventing a Party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the Parties and the subject matter of the dispute as necessary to protect that Party’s name, Confidential Information,
trade secrets, know-how, or any other proprietary rights. For actions or proceedings for injunctive relief pursuant to Section 11.4, each of the Parties irrevocably agrees that any such action shall be
brought and determined in any New York State or federal court sitting in New York County, New York, and each of the parties hereby irrevocably submits to the exclusive jurisdiction of the aforesaid courts for itself and with respect to its property,
generally and unconditionally, with regard to any such action. 

  
 -17- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 11.4    Injunctive Relief. Each Party agrees that its
obligations hereunder are necessary and reasonable to protect the other Party and its Affiliates, and expressly agrees that monetary damages could be inadequate to compensate the non-breaching Party (and its
Affiliates) for any breach of any covenant or agreement set forth herein. Each Party agrees and acknowledges that any such violation or threatened violation could cause irreparable injury to the other Party and its Affiliates and that, in addition
to any other remedies that may he available, in law, or otherwise, the non-breaching Party shall be entitled (on its own behalf and on behalf of its affiliates) to obtain injunctive relief against any
threatened breach of this Agreement or the continuation of any such breach without the necessity of proving actual damages. 

11.5    Force Majeure. Except for the payment of money, neither Party shall be held responsible for any
delay or failure in performance hereunder caused by strikes, embargoes, unexpected government requirements, civil or military authorities, acts of God, flood, earthquake, or by the public enemy or other causes reasonably beyond such Party’s
control and without such Party’s fault or negligence; provided, that the affected Party notifies the unaffected Party as soon as reasonably possible and resumes performance hereunder as soon as reasonably possible following cessation of
such force majeure event; provided, further, that no such delay or failure in performance shall continue for more than [***], In the event that a delay or failure in performance by a Party wider this Section 11.5 continues longer
than [***], the other Party may terminate this Agreement in accordance with the terms and conditions of Section 9.3 (Termination for Cause). 

11.6    Independent Contractors. The Parties are independent contractors. Nothing in this Agreement is
intended or will be deemed to constitute a partnership, agency or employer-employee relationship between the Parties. Neither Party will incur any debts or make any commitments for the other Party. 

11.7    Assignment. Except as expressly provided herein, neither this Agreement nor any interest hereunder
will be assignable or any other obligation delegable, by a Party without the prior written consent of the other Party. Either Party shall have the right to assign and otherwise transfer this Agreement in whole or in part without consent to an
Affiliate of such Party. Either Party may assign and otherwise transfer this Agreement in whole to a successor that acquires all or substantially all of its business or assets related to the subject matter of this Agreement by way of merger,
consolidation, other business reorganization, or the sale of stock or assets, but only with the prior written consent of the other Party, which authorization shall not be unreasonably conditioned, withheld or delayed; provided,
however, that it shall not be unreasonable for the Party to refuse to authorize any assignment or transfer by the other Party to a non-Affiliate [***]. This Agreement shall be binding upon successors
and permitted assigns of the Parties. Any assignment not in accordance with this Section 11.7 shall be null and void. Any permitted assignment or transfer of this Agreement shall not release the assigning or transferring Party from its
obligations under this Agreement except to the extent the Assignee expressly assumes all responsibilities and obligations associated with such assignment or transfer. 

  
 -18- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 11.8    Notices. Any notice, report, communication, or
consent required or permitted by this Agreement shall be in writing and shall be sent (a) by prepaid registered or certified mail, return receipt requested; (b) by overnight express delivery service by a nationally recognized courier;
(c) via confirmed facsimile, followed within five (5) days by a copy delivered in accordance with this Section 11.8; or (d) via e-mail or pdf, with delivery receipt and read receipt
requested, addressed to the other Party at the address shown below or at such other address as such Party gives notice hereunder. Such notice will be deemed to have been given when delivered or, if delivery is not accomplished by some fault of the
addressee, when tendered. 
  

			
	If to Customer:	  	Urovant Sciences GmbH
		  	Viaduktstrasse 8, 4051 Basel, Switzerland
		  	Attn: Head of Global Transactions
		
	With a copy to:	  	Urovant Sciences, Inc.,
		  	320 West 37th Street, 5th Floor,
		  	New York, NY 10018
		  	Attn: Legal Department
		
	If to Codexis:	  	Codexis, Inc.
		  	200 Penobscot Drive
		  	Redwood City, California 94063
		  	USA
		  	Attn: President
		  	Facsimile: [***]
		
	With a copy to:	  	Codexis, Inc.
		  	200 Penobscot Drive
		  	Redwood City, California 94063
		  	USA
		  	Attn: General Counsel
		  	Facsimile: [***]

 11.9    Severability. If any provision of this Agreement is found by a
court to be void, invalid, or unenforceable, such provision shall be reformed to comply with Applicable Law or stricken if not so conformable, so as not to affect the validity or enforceability of this Agreement; provided, that no such
reformation or striking shall be effective if the result materially changes the economic benefit of this Agreement to either Party, If any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be void, invalid,
or unenforceable, and reformation or striking of such provision would materially change the economic benefit of this Agreement to either Party, the Parties shall modify such provision in accordance with Section 11.10 (Modifications; Waivers) to
obtain a legal, valid, and enforceable provision and provide an economic benefit to the Parties that most nearly effects the Parties’ intent on entering into this Agreement. 

  
 -19- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 11.10    Modifications; Waivers. This Agreement may not be
altered, amended, supplemented, or modified in any way except by a writing signed by each Party. The failure of a Party to enforce any rights or provisions of this Agreement shall not be construed to be a waiver of such rights or provisions, or a
waiver by such Party to thereafter enforce such rights or provisions or any other rights or provisions hereunder. 

11.11    No Third Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the
benefit of any party other than those executing it. 
 11.12    Interpretation. 

(a)    Captions and Headings. The captions and headings of clauses contained in this Agreement preceding the
text of the articles, sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. 

(b)    Singular and Plural. All references in this Agreement to the singular shall include the plural where
applicable, and all references to gender shall include both genders and the neuter. 
 (c)    Articles,
Sections, and Subsections. Unless otherwise specified, references in this Agreement to any article shall include all sections, subsections, and paragraphs in such article; references in this Agreement to any section shall include all subsections
and paragraphs in such section; and references in this Agreement to any subsection shall include all paragraphs in such subsection. 

(d)    Days. All references to days in this Agreement shall mean calendar days, unless otherwise specified.

 (e)    Ambiguities. The Parties jointly drafted this Agreement. Ambiguities and uncertainties in this
Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. 

11.13    Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an
original and all of which together shall constitute one instrument. For purposes of executing this Agreement, a facsimile (including a “portable document format” (“.pdf”) image delivered via email) copy of this
Agreement, including the signature pages, will be deemed an original. 

  
 -20- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 11.14    Entire Agreement. The Parties acknowledge that
this Agreement, including, for clarity, the preamble, recitals and exhibits attached hereto, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions,
agreements, and writings with respect hereto with respect to the subject matter hereof. No trade customs, courses of dealing or courses of performance by the Parties shall be relevant to modify, supplement, or explain any term(s) used in this
Agreement. Each Party agrees and acknowledges that it has not relied on any information, data, or forecasts provided by the other Party, or discussions with the other Party, in the negotiation and execution of this Agreement. 

[Signature page follows] 

  
 -21- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 IN WITNESS WHEREOF, Customer and Codexis have executed this Agreement by their
respective duly authorized representatives on the dates identified below but the Agreement shall become effective on the Effective Date. 
  

			
	CODEXIS, INC.
		
	By:	 	/s/ Michael Aldridge

			
		
	Name:	 	Michael Aldridge

			
		
	Title:	 	SVP Corporate Strategic Development

			
		
	Date:	 	Sept-12-2017

			
	
	UROVANT SCIENCES GMBH
		
	By:	 	/s/ Sascha Bucher

			
		
	Name:	 	Sascha Bucher

			
		
	Title:	 	Head of Global Transactions

			
		
	Date:	 	Sep 14, 2017

 [***] 

  
 -22- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 [***] 

  
 -23- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 Exhibit 1.8 

Codexis Process 
 [***] 

  
 -24- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 Exhibit 3.5(d) 

Enzyme Specification 
  

			
	

	  	[***]

  
 -25- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED 

 EXECUTION VERSION 
  

 Exhibit 4.1 

Pricing for Codexis Enzyme 
 [***]

  
 -26- 

  
 [***] = CERTAIN CONFIDENTIAL
INFORMATION OMITTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]